The natural way forward: Molecular dynamics simulation analysis of phytochemicals from Indian medicinal plants as potential inhibitors of SARS-CoV-2 targets자연적인 방법: SARS-CoV-2 표적의 잠재적 억제제로서 인도 약용 식물의 식물 화학 물질의 분자 역학 시뮬레이션 분석Article Published on 2020-12-012022-09-11 Journal: Phytotherapy research : PTR [Category] SARS, 치료제, [키워드] Analysis antiviral therapy Azadirachta indica binding biological pathway Cancer combating correlation COVID-19 cross docked free energy in vivo India inhibitor inhibitors of SARS-CoV-2 life lowest main protease MM/PBSA modulate molecular molecular dynamics Molecular dynamics simulation pandemic Panic pathway Pathway enrichment analysis PCA performed phytochemicals plant Principal component principal component analysis prophylactic measure protease relative free binding energy Repurposed drug SARS-CoV-2 screened Simulation spike spike glycoprotein Spike proteins target the spike protein therapeutic agent therapeutic agents therapeutic efficacy therapy these compound these compounds withanolide [DOI] 10.1002/ptr.6868 PMC 바로가기 [Article Type] Article
Ebselen, a new candidate therapeutic against SARS-CoV-2Comment Published on 2020-12-012023-07-05 Journal: International journal of surgery (London, England) [Category] SARS, [키워드] clinical trials COVID-19 Ebselen main protease Repurposed drug SARS-CoV-2 Therapeutics [DOI] 10.1016/j.ijsu.2020.10.018 PMC 바로가기 [Article Type] Comment
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed DrugsReview Published on 2020-11-182022-10-04 Journal: Clinical and translational science [Category] SARS, 신약개발, 치료제, [키워드] Adverse assessment benefit calculated Chloroquine Combination compounds computer conducted coronavirus disease COVID‐19 database drug estimator events Favipiravir FDA food hospitalized patient Hydroxychloroquine indicated information Long medication moderate outpatients performed pharmacokinetic pharmacological Potassium QT interval Remdesivir reported Reporting Repurposed drug risk syndrome System treat was performed [DOI] 10.1111/cts.12882 PMC 바로가기 [Article Type] Review
A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2SARS-CoV-2에 대한 렘데시비르 및 기타 용도 변경 항바이러스제의 비교 분석Review Published on 2020-11-032022-08-31 Journal: EMBO Molecular Medicine [Category] SARS, 신약개발, 치료제, [키워드] Analysis Antiviral antiviral drug antiviral drugs antivirals approved Chemical biology Clinical outcome Compound COVID‐19 COVID‐19 Ebolavirus effective in vitro activity inhibit mechanism Microbiology, Virology & Host Pathogen Interaction morbidity Mortality nucleoside pandemic Patient reduce related viruses Remdesivir Repurposed drug RNA viruses SARS‐CoV‐2 SARS‐CoV‐2 shown Time to recovery Treatment strategies treatment strategy Viral viral replication Viral transmission [DOI] 10.15252/emmm.202013105 PMC 바로가기 [Article Type] Review
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity530 Published on 2020-10-272022-10-29 Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19, MERS, SARS, [키워드] acute respiratory syndrome animal model Antiviral antiviral activity antiviral drug Antiviral effect antiviral efficacy antiviral therapy Antiviral treatment baseline candidate Candidates clinical clinical trial Consensus Contact coronavirus COVID-19 COVID-19 patient COVID-19 patients dose drug effective Efficacy evaluate Evidence exhibit Favipiravir ferrets globe hamster hamsters High dose Human Hydroxychloroquine identify in vivo Infection infectious virus titer lack low dose lung Lung histopathology macaque Mild nontoxic preclinical model Prophylactic Prophylaxis protective effect reduced reduction in Repurposed drug required SARS-CoV-2 Significance significantly small molecule Spread suggested therapeutic toxic effects Transmission Treatment use of hydroxychloroquine viral disease virus virus levels virus transmission Wuhan [DOI] 10.1073/pnas.2014441117 PMC 바로가기 [Article Type] 530
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial)증상이 있는 SARS-CoV-2 감염(COVID-19)이 있는 고령자의 가정 치료: 여러 가지 실험적 치료의 효능과 내약성을 평가하기 위한 MAMS(Multi-Arm Multi-Stage) 무작위 시험에 대한 연구 프로토콜의 구조화된 요약 65세 이상 외래 환자의 입원 또는 사망 위험 감소(COVERAGE 시험)Letter Published on 2020-10-132022-08-13 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 6-mercaptopurine Abnormalities ACEi added age amodiaquine Analysis antrafenine approved ARB ARBs Arm azathioprine Blinding Bordeaux Caregivers Chloroquine chronic hepatitis Chronic kidney disease citalopram clinical Colitis Combination comparator complex conducted Control control arm COVID-19 COVID-19 pandemic criteria CYP3A4 cytochrome P450 Dasatinib death Dementia dialysis dissemination Domperidone drug Duchy Efficacy element enrolled enrolment Enterocolitis escitalopram EudraCT Evidence exclusion criteria experimental arm experimental drug Experimental drugs Favipiravir feasibility Final final analysis first symptom first symptoms floctafenine France French futility galactose GFR glafenine Glucose Glucose-6-phosphate glucose-6-phosphate dehydrogenase glucose-6-phosphate dehydrogenase deficiency Grand duchy halofantrine Health Insurance heart rate hepatic Hepatic porphyria home hospital hospitalisation Hydroxychloroquine hydroxyzine hypersensitivity Hyperuricemia Ileus Imatinib immunological incidence Inclusion increase in inducer inhibitor Interim analyses interim analysis intervals investigator investigators Isoenzyme Kidney disease Lactase Lactose liver failure Long Long QT syndrome Luxembourg malabsorption mefloquine mercaptopurine metabolism multi multi-arm nasopharyngeal Nasopharyngeal swab New Nilotinib not blinded number nursing home nursing homes objective Older Open-label open-label trial other treatment other treatments outcome Outpatient P450 Paris participant Patient performed phase Piperaquine Positive test Prevent primary care Primary outcome proportion protocol pyrazinamide QTc interval randomisation randomised Randomized Randomly receive recruited Region Registered regulatory authority repaglinide replaced REPLACED BY reported Repurposed drug residence Safety Monitoring Board Sample size SARS-CoV-2 SARS-COV-2 infection scale Stage Standard statistician statisticians status stratified Study protocol submitted symptomatic SARS-CoV-2 infection Tablet telmisartan tested theophylline Toxicity Trace element trace elements treated Treatment treatment arm Trial Trial registration Version virus Virus Disease Vitamin vitamins Warfarin [DOI] 10.1186/s13063-020-04619-1 PMC 바로가기 [Article Type] Letter
Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical TrialsPerspective Piece Published on 2020-09-232022-10-28 Journal: The American Journal of Tropical Medicine and Hygi [Category] COVID-19, SARS, [키워드] Anecdotal caused clinical Clinical efficacy Compound compounds COVID-19 COVID-19 pandemic deaths demonstrated derivative derivatives develop Dexamethasone Efficacy effort evaluate event Evidence fevers herbal compound herbal medicines highlight immunological effects malaria Map pharmacological Potential Prevent Randomized controlled trial RCTs Remdesivir reported Repurposed drug Research Respiratory tract infections road SARS-CoV-2 seriously ill patients subsequent treat Treatment [DOI] 10.4269/ajtmh.20-0820 PMC 바로가기 [Article Type] Perspective Piece
Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood ArenaPharmacology Published on 2020-09-172022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] absence acute respiratory syndrome Anti-inflammatory antibody antimalarial antiparasitic drug Antiviral arena available data benefit candidate Candidates caused cellular therapy China chloroquine/hydroxychloroquine city claimed clinical manifestation clinical trial clinically controls convalescent plasma coronavirus Coronavirus disease 2019 COVID-19 criteria cytokine drug Drug repurposing effective Epidemics evaluated Evidence explain Favipiravir global pandemic Guidance identify Immunotherapy imperative IMPROVE in vitro activity include Inconclusive initiation of treatment interferon investigational agent Ivermectin lack MERS Middle East monoclonal Natural killer cells observational study outcome outcomes pathology pathophysiology Patient patient selection Pneumonia Population Potential Potential treatment Prevent progression receptor Remdesivir Repurposed drug responsible SARS-CoV-2 severe acute respiratory syndrome coronavirus 2 small sample size stem cell syndrome target the disease the patient the timing Therapeutic strategies therapeutic strategy therapy Treatment treatment guidelines umifenovir understanding Understood Vaccine virus Wuhan [DOI] 10.3389/fphar.2020.585888 PMC 바로가기 [Article Type] Pharmacology
Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)Review Published on 2020-09-162022-10-04 Journal: Clinical and translational science [Category] SARS, 유전자 메커니즘, 치료제, [키워드] acute respiratory syndrome Biomarker coronavirus disease COVID‐19 drug drugs help indicated pandemic pharmacogenetic potential therapies recommendation Repurposed drug SARS‐CoV‐2 therapeutic variety [DOI] 10.1111/cts.12866 PMC 바로가기 [Article Type] Review
Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic reviewInfectious Diseases Published on 2020-09-142022-10-28 Journal: BMJ Open [Category] COVID-19, Fulltext, SARS, [키워드] ACE inhibitor ACE2 adverse events Affect agonist angiotensin receptor blocker animal model anti-inflammatory drug appear ARB ARBs attenuate blocker CINAHL clinician Cochrane Library concerning COVID-19 COVID-19 disease downregulate downregulation drug Effects Evidence exacerbate examined Gene Expression Human human lung in vivo indicate insulin Laboratory animal Lungs media NSAIDS objective outcome pathogenic Patient peptide Placebo prescribed medications public health reported Repurposed drug respiratory infections Result review screened systematic review the SARS-CoV-2 virus Trial upregulation Web of Science [DOI] 10.1136/bmjopen-2020-040644 PMC 바로가기 [Article Type] Infectious Diseases